Bristol-Myers Squibb Co (BMY)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

345 PARK AVE NEW YORK, NY 10154

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare-related products. The Company has three segments: Pharmaceuticals, Nutritionals and ConvaTec. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The other two segments Nutritionals and ConvaTec comprise the Company's Health Care Group. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. The ConvaTec segment consists of the ostomy, wound and skin care business.

Data based on most recent fiscal year report
Market Cap102.736 Billion Shares Outstanding1.637 Billion Avg Volume12.73 Million
1-Yr BETA vs S&P TR0.74 Current Ratio1.55 Quick Ratio1.43
View SEC Filings from BMY instead.
Q2 2018 All Institutions Hedge Funds 1
To trade BMY now:
Filers who had this stock in their top 10: 40 7 (0.67%)
13F Filers holding this stock: 1634 128 (12.24%)
Aggregate 13F shares on 06/30/2018: 1.179 Billion 73.343 Million
Aggregate 13F shares on 03/31/2018: 1.172 Billion 71.959 Million
Percent change: 0.59% 1.92%
Funds creating new positions: 91 16
Funds Adding to an existing position: 562 47
Funds closing out their position: 130 39
Funds reducing their position: 739 48
Heat Map Ranking for 06/30/2018 122
Heat Map Ranking for 03/31/2018 36
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BMY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to

Exclude:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

2 Thousand total shares from 3 transactions

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Acquired or Disposed Shares Owned Following Transaction Direct/Indirect Ownership

BIONDI PAUL - Officer SVP, HEAD OF STRATEGY & BD

2018-10-02 M 592 a 592 direct

BIONDI PAUL - Officer SVP, HEAD OF STRATEGY & BD

2018-10-02 M 592 d 1,776 direct

BIONDI PAUL - Officer SVP, HEAD OF STRATEGY & BD

2018-10-02 F 292 d 300 direct

ARDUINI PETER J - Director

2018-09-30 A 524 a 14,136 direct

STORCH GERALD L - Director

STORCH GERALD L - Director

2018-09-30 A 524 a 43,493 direct

BASELGA JOSE - Director

2018-09-30 A 386 a 3,681 direct

GROBSTEIN MICHAEL - Director

2018-09-30 A 282 a 74,076 direct

SAMUELS THEODORE R. II - Director

2018-09-30 A 493 a 8,395 direct

EMMENS MATTHEW - Director

2018-09-30 A 524 a 9,439 direct

LACY ALAN J - Director

2018-09-30 A 493 a 64,079 direct

PALIWAL DINESH C - Director

2018-09-30 A 493 a 21,707 direct

STORCH GERALD L - Director

STORCH GERALD L - Director

2018-09-30 A 524 a 43,493 direct

VOUSDEN KAREN H - Director

2018-09-30 A 126 a 3,585 direct

BERTOLINI ROBERT J - Director

2018-09-30 A 534 a 9,332 direct

DUBOW ADAM - Officer CHIEF COMPLIANCE & ETHICS OFFI

2018-09-03 F 273 d 15,222 direct

DUBOW ADAM - Officer CHIEF COMPLIANCE & ETHICS OFFI

2018-09-03 M 797 a 15,495 direct

DUBOW ADAM - Officer CHIEF COMPLIANCE & ETHICS OFFI

2018-09-03 M 797 d 0 direct

SANTIAGO KAREN MURPHY - Officer CONTROLLER

2018-09-01 M 641 a 4,057 direct

SANTIAGO KAREN MURPHY - Officer CONTROLLER

2018-09-01 M 641 d 1,283 direct

SANTIAGO KAREN MURPHY - Officer CONTROLLER

2018-09-01 F 220 d 3,837 direct
Click here to report any possible errors with this stock listing.

Elevate your investments